PD-L1 expression in papillary renal cell carcinoma.
PD-L1 expression in papillary renal cell carcinoma.
复制标题
DOI：
10.1186/s12894-016-0195-x
复制
发表时间：
2017-01-13
期刊：
影响因子：
2
通讯作者：
Eto M
中科院分区：
文献类型：
--
作者：
Motoshima T;Komohara Y;Ma C;Dewi AK;Noguchi H;Yamada S;Nakayama T;Kitada S;Kawano Y;Takahashi W;Sugimoto M;Takeya M;Fujimoto N;Oda Y;Eto M
癌细胞的免疫逃逸或耐受被认为与癌症的进展密切相关。程序性死亡-1 （Programmed death-1, PD-1）是一种表达在活化T细胞上的抑制性受体，有几种类型的癌细胞被发现表达PD-1配体1 （PD-L1）和配体2 （PD-L2）。在本研究中，我们研究了PD-L1/2在乳头状肾细胞癌（pRCC）中的表达。我们在102例患者中发现29例PD-L1表达，但未见PD-L2表达。PD-L1表达与包括无进展生存期和总生存期在内的任何临床病理因素均无显著相关性。2型pRCC中pd - l1阳性病例的发生率（36%）高于1型pRCC (22%)；而0分病例的百分比差异无统计学意义（卡方检验p值= 0.084）。2型患者中PD-L1高表达病例的频率（23%）高于1型患者（11%），3/4级患者中PD-L1高表达病例的频率（21%）高于1/2级患者（13%）。然而，在pRCC中，PD-L1的表达与所有临床病理因素之间没有明显的关联。癌细胞中PD-L1的高表达可能与pRCC中高组织学级别的恶性肿瘤有关。PD-L1蛋白的评估可能仍然有助于预测使用免疫检查点抑制剂的抗癌免疫治疗的疗效，但对预测临床预后没有帮助。本文的在线版本（doi:10.1186/s12894-016-0195-x）包含补充材料，可供授权用户使用。
The immune escape or tolerance of cancer cells is considered to be closely involved in cancer progression. Programmed death-1 (PD-1) is an inhibitory receptor expressed on activating T cells, and several types of cancer cells were found to express PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2). In the present study, we investigated PD-L1/2 expression in papillary renal cell carcinoma (pRCC). We found PD-L1 expression in 29 of 102 cases, but no PD-L2 expression was seen. PD-L1 expression was not significantly correlated with any clinicopathological factor, including progression-free survival and overall survival. The frequency of PD-L1-positive cases was higher in type 2 (36%) than in type 1 (22%) pRCC; however, there was no significant difference in the percentages of score 0 cases (p value = 0.084 in Chi-square test). The frequency of high PD-L1 expression cases was higher in type 2 (23%) than in type 1 (11%), and the frequency of high PD-L1 expression cases was higher in grade 3/4 (21%) than in grade 1/2 (13%). However, no significant association was found between PD-L1 expression and all clinicopathological factors in pRCC. High expression of PD-L1 in cancer cells was potentially associated to highly histological grade of malignancy in pRCC. The evaluation of the PD-L1 protein might still be useful for predicting the efficacy of anti-cancer immunotherapy using immuno-checkpoint inhibitors, however, not be useful for predicting the clinical prognosis. The online version of this article (doi:10.1186/s12894-016-0195-x) contains supplementary material, which is available to authorized users.